Epstein David M. 4

What Happened David M. Epstein, a director of Gyre Therapeutics, reported a grant (code A) of a derivative award on 2026-06-10 that represents the right to acquire 40,000 shares of the company’s common stock. The filing records the transaction at $0.00 (derivative award), meaning this was a compensatory grant rather than an open‑market purchase or sale.

Key Details

• Transaction date: June 10, 2026; Form filed June 30, 2026 (appears late vs. the typical 2-business‑day Form 4 deadline).
• Transaction type: Grant/award of a derivative (option/right) for 40,000 shares; reported price $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The option vests in 12 equal monthly installments through June 10, 2027, subject to continued service (F1).
• Filing timeliness: Filed 20 days after the transaction date — Form 4s are normally due within two business days, so this filing appears untimely (transactionTimeliness = L).

Context This was a time‑based compensatory award (an option/right that vests monthly), not an exercise or sale of existing shares. Because the award vests over a year and no shares were reported as exercised or sold, there is no immediate change to market‑held shares from this filing. Grants to directors are common for compensation and retention; they are informative about incentive alignment but do not by themselves signal a buying or selling decision.